Middle East & Africa Clinical Trial Imaging Market Forecast to 2028 -Regional Analysis - by Modality [Tomography, Magnetic Resonance Imaging (MRI), Ultrasound, Positron Emission Tomography (PET), X-Ray, Echocardiography, and Others], Offering (Operational

Middle East & Africa Clinical Trial Imaging Market Forecast to 2028-Regional Analysis- by Modality [Tomography, Magnetic Resonance Imaging (MRI), Ultrasound, Positron Emission Tomography (PET), X-Ray, Echocardiography, and Others], Offering (Operational Imaging Services, Imaging Software, Read Analysis Services, Trial Design and Consulting Services, and Others), and End User [Contract Research Organizations (CROs), Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Others]

The Middle East & Africa clinical trial imaging market is expected to grow from US$ 54.01 million in 2023 to US$ 72.43 million by 2028; it is estimated to register a CAGR of 6.0% from 2023 to 2028.

In-Silico Imaging Clinical Trials to Fuel Middle East & Africa Clinical Trial Imaging Market During Forecast Period

According to a 2023 report by the SPIE, clinical trials are expensive and lengthy, which causes delays in regulatory evaluation and significantly affects patients’ access to novel and high-quality pharmaceutical products. Adoption of in-silico imaging attributes evaluating safety and effectiveness of imaging technologies with less burden than clinical trials as they provide minimal errors. In-silico imaging in clinical trials comprises computer simulation of an entire imaging system/its components (such as source, object, task, observer components, etc.), which assists research, development, optimization, technology assessment, and regulatory evaluation. In-silico imaging trials are vital in evaluating new medical imaging systems. Incorporating in-silico trials improved lesion detection performance favoring tomosynthesis for all breast sizes and lesion types. Findings of VICTRE reveal that in-silico imaging trials and computer simulation imaging tools are likely to be viable sources of evidence in the regulatory evaluation of imaging devices, which is expected to provide lucrative opportunities for the growth of the Middle East & Africa clinical trial imaging market during the forecast period.

Middle East & Africa Clinical Trial Imaging Market Overview

The clinical trial imaging market in the Middle East & Africa is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. South Africa is expected to account for the largest market share. The growth of the clinical trial imaging market in this region is attributed to the availability of funds for R&D and various initiatives taken by the government. According to a recent Gulf Cooperation Council (GCC) report, the region made the most prominent healthcare infrastructure investments globally between 2010 and 2020. The government of South Africa has started providing investment incentives, taking measures to protect intellectual rights, simplifying tax rules, and levying better regulatory policies to attract foreign investments to nurture the clinical trial landscape in the country. Moreover, the number of trials has been increasing due to high recruitment rates and an improved regulatory environment in the country. South Africa receives substantial sponsorships from innovative pharmaceutical companies for conducting clinical research, with no signs of slowing down. Thus, the progressing clinical research industry bolsters the growth of the clinical trial imaging market in the country.

Middle East & Africa Clinical Trial Imaging Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Clinical Trial Imaging Market Segmentation

The Middle East & Africa clinical trial imaging market is segmented on the basis of modality, offering, end user, and country.

Based on modality, the Middle East & Africa clinical trial imaging market is segmented into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), X-ray, echocardiography, and others. The tomography segment registered the largest market share in 2023.

Based on offering, the Middle East & Africa clinical trial imaging market is segmented into operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. The operational imaging services segment held the largest market share in 2023.

Based on end user, the Middle East & Africa clinical trial imaging market is segmented into contract research organizations (CROs), pharmaceutical and biotechnology companies, academic and research institutes, and others. The contract research organizations (CROs) segment held the largest market share in 2023.

Based on country, the market is segmented into UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. South Africa dominated the market share in 2023.

eResearch Technology Inc, ICON PLC, Medical Metrics Inc, VIDA Diagnostics Inc, and WCG Clinical Inc are the leading companies operating in the Middle East & Africa clinical trial imaging market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa clinical trial imaging market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa clinical trial imaging market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the clinical trial imaging market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution